Menu
GALLERY
Founded in 2006, Allosterix is an Israeli drug design company with core competencies in the field of drug discovery and design. Allosterix has developed a patent-pending technology for locating allosteric sites and peptidic drug design. Our approach to drug design is unique because we create inhibitors based on the principles of allostery. The advantage to this drug-design approach is simple: specificity. With our approach, selectivity is inherent in each peptidic inhibitor.
All
enzyme
inhibitors developed to date have been orthosteric in nature, meaning
they target the active of the enzyme. Almost always, these active sites
are conserved among families of enzymes and much time and effort is
expended to create drugs with a selectivity profile fit for human use.
In contrast, allosteric sites are located distal to the active site, in
non-conserved regions of the enzyme. Therefore, by designing drug to
these unique regions we can produce inhibitors with unprecedented
selectivity profile. This is a departure from any previous drug design
strategy aimed at inhibiting enzymatic function.
Our unique allosteric inhibitors show little to no reactivity with
other enzymes, evenly very closely related enzymes. This translates
into low incidence of triggering unwanted side effects or toxic
effects. Therefore, an allosteric inhibitor has a significantly higher
chance of success at the clinical stage to becoming a drug.
Research and Innovation:
Tackling debilitating diseases
Autoimmune
disorders such as arthritis and inflammation, cancer and
Alzheimer’s
disease are
just four of the many conditions of our time that have devastating
consequences. Despite the major progress being made in their treatment,
there is still a huge need for better therapies to control and reverse
the progression of these chronic, debilitating diseases. We are
committed to creating safe drugs that improve patient’s
quality
of life and prolong their survival.
Back to Top
| |
|